These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

52 related items for PubMed ID: 2806070

  • 1. [The role of the system of reverse capture of dopamine in the development of experimental Parkinsonism under the effect of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine and its pyridine analogs].
    Bachurin SO, Soliakov LS, Lermontova NN, Tkachenko SE, Kalashnikov VV, Serkova TP, Petrova LN.
    Dokl Akad Nauk SSSR; 1989; 307(3):740-3. PubMed ID: 2806070
    [No Abstract] [Full Text] [Related]

  • 2. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K, Kondo T, Narabayashi H.
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [Abstract] [Full Text] [Related]

  • 3. [Effect of acidic fibroblast growth factor on experimental parkinsonism and levels of dopamine and its metabolites in the striatum of mice of various ages].
    Kucherianu VG, Kryzhanovskiĭ GN, Kudrin VS, Iurasov VV, Nikushkin EV, Zhigal'tsev IV.
    Biull Eksp Biol Med; 1999 May; 127(5):502-5. PubMed ID: 10399565
    [No Abstract] [Full Text] [Related]

  • 4. Amine fluorescence histochemical investigation of the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)-induced parkinsonian mice.
    Mizukawa K, Ogawa N, Sora YH.
    Res Commun Chem Pathol Pharmacol; 1988 Jan; 59(1):121-8. PubMed ID: 3258432
    [Abstract] [Full Text] [Related]

  • 5. Effects of nimodipine on the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced depletions in the biogenic amine levels in mice.
    Gerlach M, Russ H, Winker J, Witzmann K, Traber J, Stasch JP, Riederer P, Przuntek H.
    Arzneimittelforschung; 1993 Apr; 43(4):413-5. PubMed ID: 7684224
    [Abstract] [Full Text] [Related]

  • 6. [Evaluation of the capability of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and pyridine derivatives to evoke parkinsonism].
    Lermontiva NN, Soliakov LS, Bachurin SO, Tkachenko SE, Serkova TP.
    Biull Eksp Biol Med; 1989 Jun; 107(6):699-701. PubMed ID: 2790166
    [Abstract] [Full Text] [Related]

  • 7. Behavioral and biochemical effects of 4-phenylpyridine, 2-phenylpyridine, and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in rodents.
    Hassan MN, Thakar JH, Grimes JD.
    Adv Neurol; 1990 Jun; 53():219-23. PubMed ID: 2239461
    [No Abstract] [Full Text] [Related]

  • 8. Riluzole and experimental parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice.
    Boireau A, Dubédat P, Bordier F, Peny C, Miquet JM, Durand G, Meunier M, Doble A.
    Neuroreport; 1994 Dec 20; 5(18):2657-60. PubMed ID: 7696626
    [Abstract] [Full Text] [Related]

  • 9. [The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome].
    Iurasov VV, Kucherianu VG, Kudrin VS, Zhigal'tsev IV, Nikushkin EV, Sandalov IuG, Kaplun AP, Shvets VI.
    Biull Eksp Biol Med; 1997 Feb 20; 123(2):150-3. PubMed ID: 9280483
    [No Abstract] [Full Text] [Related]

  • 10. Synthetic bovine proline-rich-polypeptides generate hydroxyl radicals and fail to protect dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity in mice.
    Knaryan VH, Samantaray S, Varghese M, Srinivasan A, Galoyan AA, Mohanakumar KP.
    Neuropeptides; 2006 Aug 20; 40(4):291-8. PubMed ID: 16712929
    [Abstract] [Full Text] [Related]

  • 11. [Clinical and biochemical parameters of parkinsonism induced by 1-methyl-4-phenyl-1,2,2,6-tetrahydropyridine and its methyl-phenyl and methoxy-phenyl derivatives in C57Bl/6 mice].
    Lermontova NN, Soliakov LS, Bachurin SO, Serkova TP, Petrova LN, Dranyĭ OA, Tkachenko SE, Kalashnikov VV.
    Biull Eksp Biol Med; 1990 Oct 20; 110(10):397-9. PubMed ID: 2279092
    [Abstract] [Full Text] [Related]

  • 12. Endogenous analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: indoleamine derived tetrahydro-beta-carbolines as potential causative factors in Parkinson's disease.
    Collins MA, Neafsey EJ, Cheng BY, Hurley-Gius K, Ung-Chhun NA, Pronger DA, Christensen MA, Hurley-Gius D.
    Adv Neurol; 1987 Oct 20; 45():179-82. PubMed ID: 3493625
    [No Abstract] [Full Text] [Related]

  • 13. [Mechanism of induction of parkinsonism by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a dopaminergic neurotoxin].
    Hirata Y, Nagatsu T.
    Tanpakushitsu Kakusan Koso; 1986 Apr 20; 31(5):398-409. PubMed ID: 3520683
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
    Gal S, Zheng H, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct 20; 95(1):79-88. PubMed ID: 16181414
    [Abstract] [Full Text] [Related]

  • 17. N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the monkey: neurochemical pathology and regional brain metabolism.
    Mitchell IJ, Cross AJ, Sambrook MA, Crossman AR.
    J Neural Transm Suppl; 1986 Oct 20; 20():41-6. PubMed ID: 3462325
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
    Holmer HK, Keyghobadi M, Moore C, Meshul CK.
    Neuroscience; 2005 Oct 20; 136(1):333-41. PubMed ID: 16198485
    [Abstract] [Full Text] [Related]

  • 20. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism.
    Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL.
    Neuropharmacology; 2006 Jul 20; 51(1):112-20. PubMed ID: 16678218
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 3.